Aimovig Injection
Product Images NDC 55513-841

Product Visual Gallery

This gallery contains 66 technical images submitted to the FDA as part of the official labeling for Aimovig (NDC 55513-841). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Change From Baseline In Monthly Migraine Days In Study 1a (Aimovig 01)

A line graph depicting the change from baseline in monthly migraine days over a 6-month period, comparing placebo with AIMOVIG 70 mg and 140 mg doses administered once monthly. The y-axis shows change from baseline in migraine days, and the x-axis represents time from baseline through month 6.*

FDA Label Image

Figure 2: Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 4 To 6 By Treatment Group In Study 1 (Aimovig 02)

A bar graph comparing the percent of patients experiencing fewer migraine days per month across three groups: placebo (N=289), AIMOVIG 70 mg QM (N=296), and AIMOVIG 140 mg QM (N=302). The x-axis shows ranges of migraine day reductions per month, and the y-axis shows the percentage of patients. The graph includes a category for no change or more migraine days per month.*

FDA Label Image

Figure 3: Change From Baseline In Monthly Migraine Days In Study 2a (Aimovig 03)

A line graph comparing change from baseline in monthly migraine days over 3 months between placebo and AIMOVIG 70 mg QM. The graph shows mean changes with error bars, indicating greater reduction in migraine days for AIMOVIG 70 mg QM compared to placebo at each monthly interval.*

FDA Label Image

Figure 4: Distribution Of Change From Baseline In Monthly Migraine Days At Month 3 By Treatment Group In Study 2 (Aimovig 04)

Bar chart comparing the percent of patients with fewer migraine days per month between placebo and AIMOVIG 70 mg QM groups. The x-axis shows categories of reduced migraine days ranging from '>12 to 14' down to '>0 to 2' and 'No change or more migraine days per month.' The y-axis represents the percent of patients. AIMOVIG shows higher percentages of patients with reductions from '>6 to 8' to '>0 to 2' fewer migraine days compared to placebo.*

FDA Label Image

Figure 5: Change From Baseline In Monthly Migraine Days In Study 3a (Aimovig 05)

A line graph depicting the change from baseline in monthly migraine days over three months for Placebo, AIMOVIG 70 mg, and AIMOVIG 140 mg dosages. The vertical axis shows change from baseline in monthly migraine days, and the horizontal axis shows time points at Baseline, Month 1, Month 2, and Month 3. Error bars indicating variability are included for each group at each time point.*

FDA Label Image

Figure 6: Distribution Of Change From Baseline In Monthly Migraine Days At Month 3 By Treatment Group In Study 3 (Aimovig 06)

A bar chart illustrating the percentage of patients experiencing fewer migraine days per month across three groups: Placebo, AIMOVIG 70 mg every month, and AIMOVIG 140 mg every month. The x-axis categorizes the reduction in migraine days, while the y-axis shows the percent of patients. Data compares effectiveness on reducing migraine frequency among the groups.*

FDA Label Image

Aimovig 07

Illustration showing parts of the AIMOVIG subcutaneous injection pen before and after use. Before use features a purple start button, expiration date, view window displaying medicine, white cap, and green safety guard covering the needle. After use shows the green safety guard, yellow window indicating injection completion, expiration date, and a removed white cap placed below.*

FDA Label Image

Guide To Parts (Aimovig 08)

An instructional illustration showing a close-up view of a prefilled syringe labeled AIMOVIG (erenumab-aooe) injection. It highlights three parts: a white cap on the syringe tip, a transparent window on the barrel, and the visible medicine inside the syringe barrel. This diagram assists users in identifying key syringe components before subcutaneous administration.*

FDA Label Image

Read This Before You Inject. (Aimovig 09)

An instructional diagram depicting the components for subcutaneous injection of AIMOVIG (erenumab-aooe). It shows a prefilled pen injector, two alcohol swabs, two round tablets (likely illustrative), two adhesive bandages, and a carrying case or container. This image likely demonstrates preparation and supplies needed for AIMOVIG injection.*

FDA Label Image

Pinch Method (Aimovig 10)

An instructional illustration showing recommended subcutaneous injection sites on a human body for a medication. Sites labeled include the upper arm, stomach area (abdomen), and thigh. The diagram assists in locating appropriate injection areas for subcutaneous administration.*

FDA Label Image

G Hold The Stretch Or Pinch. With The White Cap Off, Place The Autoinjector On Your Skin At 90 Degrees. (Aimovig 11)

An instructional illustration showing the removal of the cap from an Aimovig (erenumab-aooe) autoinjector pen prior to subcutaneous injection. The image depicts two hands pulling the cap off the pen in preparation for use.*

FDA Label Image

H Firmly Push The Autoinjector Down Onto Skin Until The Autoinjector Stops Moving. (Aimovig 12)

Illustration showing a clock face with 5 minutes highlighted in red, indicating a 5-minute interval. No additional product information is visible.*

FDA Label Image

I When You Are Ready To Inject, Press The Purple Start Button. You Will Hear A Click. (Aimovig 13)

An instructional illustration demonstrating the 'stretch method' for skin preparation or injection technique. It shows two fingers stretching the skin horizontally in opposite directions, indicating how to properly stretch the skin before injection.*

FDA Label Image

J Keep Pushing Down On Your Skin. Your Injection Could Take About 15 Seconds. When The Injection Is Complete, You May Hear Or Feel A Click And The Window Will Turn Yellow. (Aimovig 14)

A pill tablet with the imprint 'OR' on one side, in white letters on a black, rounded rectangular tablet. No additional product information is visible in the image.*

FDA Label Image

K Discard The Used Autoinjector And The White Cap. (Aimovig 15)

Illustration showing the 'Pinch method' for subcutaneous injection. It depicts fingers pinching the skin and an arrow indicating the direction for inserting the injection needle. The image is instructional and relates to subcutaneous administration technique.*

FDA Label Image

Aimovig 16

Illustration showing the correct subcutaneous injection technique for AIMOVIG (erenumab-aooe) injection. It depicts a hand holding the pen injector at a 90-degree angle to the skin, highlighting the proper placement of the injection device tip against the skin.*

FDA Label Image

This Product Contains Dry Natural Rubber (Aimovig 17)

An instructional illustration showing the proper technique for administering a subcutaneous injection with a pen device. One hand holds the injection pen perpendicular to the skin, while the other hand gently pinches the skin. A downward arrow indicates the direction to press the pen for injection.*

FDA Label Image

Do Not Reuse (Aimovig 18)

Illustration showing the administration of AIMOVIG (erenumab-aooe) injection subcutaneously. The image depicts a person holding an AIMOVIG prefilled autoinjector at a right angle to the skin, pressing down to deliver the dose, with an arrow indicating downward pressure and a 'click' sound to signify activation.*

FDA Label Image

Caution,consult Accompanying Documents (Aimovig 19)

An instructional illustration showing a hand holding an AIMOVIG prefilled autoinjector pen for subcutaneous injection. The diagram demonstrates pressing the pen firmly into the skin to administer the injection, with a 'click' sound indicated to confirm activation.*

FDA Label Image

D Prepare And Clean Your Injection Site. (Aimovig 20)

Instructional illustration showing a timer set to 15 seconds and a close-up view of a yellow fluid inside a window of a device, likely indicating a step in the use of an injection product, AIMOVIG (erenumab-aooe).*

FDA Label Image

E Pull Gray Needle Cap Straight Out And Away From Your Body, Only When You Are Ready To Inject. Do Not Leave The Gray Needle Cap Off For More Than 5 Minutes. This Can Dry Out The Medicine. (Aimovig 21)

The image depicts a close-up view of the cap of an injection vial or prefilled syringe for AIMOVIG, a human prescription drug containing erenumab-aooe. The cap shown is two-toned with a teal and gray color scheme, consistent with injection packaging typically used for subcutaneous administration by Amgen, Inc.*

FDA Label Image

F Pinch Your Injection Site To Create A Firm Surface. (Aimovig 22)

An instructional illustration showing a hand placing an AIMOVIG injection autoinjector pen into a red carrying case. The image demonstrates the proper storage or handling of the subcutaneous injection device for delivery of erenumab-aooe.*

FDA Label Image

G Hold The Pinch. With The Gray Needle Cap Off, Insert The Syringe Into Your Skin At 45 To 90 Degrees. (Aimovig 23)

FDA Label Image

H Place Your Finger On The Plunger Rod. Using Slow And Constant Pressure, Push The Plunger Rod All The Way Down Until The Prefilled Syringe Stops Moving. (Aimovig 24)

FDA Label Image

I When Done, Release Your Thumb, And Gently Lift The Syringe Off Of Your Skin. (Aimovig 25)

FDA Label Image

J Discard The Used Syringe And The Gray Needle Cap. (Aimovig 26)

FDA Label Image

This Product Contains Dry Natural Rubber (Aimovig 27)

Illustration showing parts of an AIMOVIG injection pen before and after use. The pen is labeled with a gray start button, expiration date, window displaying medicine, and an orange cap on with a yellow safety guard indicating the needle inside before use. After use, the window turns yellow to show injection completion, the orange cap is off, and the yellow safety guard remains on.*

FDA Label Image

Principal Display Panel1 X 70 mg/ml Prefilled Autoinjectorndc 55513-841-01rx Onlyaimovig™(erenumab-aooe) Injection70 mg/ml70 mg/mlprefilled Autoinjector For Subcutaneous Use Only Store At 2°c To 8°c (36°f To 46°f) In Original Carton To Protect From Light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion. Keep Out Of The Sight And Reach Of Children. For More Information, Go To Aimovig.com Orcall 1-800-77-amgen (1-800-772-6436). Caution, Consultaccompanying Documents Do Not Reuse This Product Containsdry Natural Rubber.no U.s. Standard Of Potency (Aimovig 28)

An instructional diagram showing a close-up view of a blue injection pen with an orange cap attached. The pen features a window displaying the medicine inside. Labels point to the orange cap, the window, and the medicine within the window.*

FDA Label Image

Principal Display Panel2 X 70 mg/ml Prefilled Autoinjectorsndc 55513-841-02rx Onlyaimovig™(erenumab-aooe) Injection70 mg/ml70 mg/ml140 mg/2 mL70 mg/mlprefilled Autoinjectors For Subcutaneous Use Only Store At 2°c To 8°c (36°f To 46°f) In Original Carton To Protect From Light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion. Keep Out Of The Sight And Reach Of Children. For More Information, Go To Aimovig.com Orcall 1-800-77-amgen (1-800-772-6436). Caution, Consultaccompanying Documents Do Not Reuse This Product Containsdry Natural Rubber.no U.s. Standard Of Potency (Aimovig 29)

Illustration showing the components of AIMOVIG injection kit by Amgen, Inc. It includes a prefilled pen injector labeled 140 mg/0.7 mL, two alcohol prep pads, two circular adhesive pads, and a pink sharps disposal container with lid.*

FDA Label Image

Aimovig 30

An instructional diagram showing recommended subcutaneous injection sites for AIMOVIG (erenumab-aooe). Injection areas highlighted include the upper arm, stomach area (abdomen), and thigh on a human figure.*

FDA Label Image

Aimovig 31

An instructional diagram showing hands removing the orange cap from a pen-style injector, likely representing an AIMOVIG (erenumab-aooe) subcutaneous injection device. The image visually guides the user on how to prepare the injection pen for use.*

FDA Label Image

Aimovig 32

An instructional diagram depicting a clock face with a time interval of 5 minutes highlighted in red. The image visually represents a five-minute duration, often used in instructions or timing-related guidance.*

FDA Label Image

Aimovig 33

Illustration showing the stretch method for preparing skin before an injection. The image depicts fingers stretching the skin horizontally with arrows indicating the direction of the stretch.*

FDA Label Image

Aimovig 34

FDA Label Image

Aimovig 35

An instructional illustration demonstrating the pinch method for subcutaneous injection. It shows a hand pinching the skin on an arm to create a fold, preparing the site for injection. The image is intended to guide proper technique for administering a subcutaneous injection.*

FDA Label Image

Aimovig 36

An instructional illustration showing the proper technique for subcutaneous injection using the AIMOVIG autoinjector device. It depicts a hand holding the device at a 90-degree angle to the injection site on the skin, with a close-up inset indicating correct positioning of the device tip with a green check mark.*

FDA Label Image

Aimovig 37

An instructional illustration showing a hand holding an injection pen device against a bent knee, indicating administration of a subcutaneous injection. An arrow points downward from the device to the skin, demonstrating the injection technique for a subcutaneous route.*

FDA Label Image

Aimovig 38

An instructional illustration showing a hand injecting AIMOVIG (erenumab-aooe) injection subcutaneously. The image depicts pressing the injector down into the skin with a 'click' sound indicated, demonstrating proper injection technique.*

FDA Label Image

Aimovig 39

An instructional illustration showing the use of an injection device designed for subcutaneous administration. The image shows a person holding the device upright with one hand while pressing it downwards against the skin on the arm with the other hand, accompanied by the word "click" to indicate activation of the injection mechanism.*

FDA Label Image

Aimovig 40

Instructional diagram showing a timer set for 15 seconds alongside an image of a test device with a yellow strip. The image likely represents a timed step in using a diagnostic or drug delivery device.*

FDA Label Image

Aimovig 41

FDA Label Image

Aimovig 42

An instructional illustration showing a hand holding an AIMOVIG prefilled injection device, positioned above a red sharps disposal container with an open lid. A bold black arrow indicates the motion of disposing the injection device into the container after use.*

FDA Label Image

Aimovig 43

FDA Label Image

Aimovig 44

FDA Label Image

Aimovig 45

FDA Label Image

Aimovig 46

FDA Label Image

Aimovig 47

An instructional diagram showing a syringe before and after use for AIMOVIG injection. The syringe parts are labeled including plunger rod, finger flange, label and expiration date, syringe barrel, medicine inside before use, and gray needle cap on. After use, the used plunger rod, finger flange, label and expiration date, used syringe barrel, used needle, and gray needle cap off are indicated.*

FDA Label Image

Aimovig 48

An instructional illustration showing a hand opening a packaging containing a prefilled syringe for injection. The image likely relates to the handling or preparation of the AIMOVIG erenumab-aooe subcutaneous injection product.*

FDA Label Image

Aimovig 49

An instructional illustration showing hands holding and assembling a prefilled syringe inside a box. Two red arrows indicate steps in removing or preparing the syringe for use, consistent with subcutaneous injection device handling.*

FDA Label Image

Aimovig 50

Illustration of a subcutaneous injection device labeled with parts including syringe barrel, gray needle cap, medicine, label and expiration date, plunger rod, and finger flange. The diagram shows the components of a prefilled syringe typically used for self-administration of drugs like AIMOVIG (erenumab-aooe).*

FDA Label Image

Aimovig 51

Illustration showing components of a subcutaneous injection kit for AIMOVIG (erenumab-aooe). The image includes a prefilled syringe, two alcohol prep pads, two adhesive bandages, and a red sharps disposal container with an open lid.*

FDA Label Image

Aimovig 52

An instructional diagram showing recommended subcutaneous injection sites for a human figure. The highlighted areas include the upper arm, stomach area (abdomen), and thigh, each labeled accordingly to guide proper injection placement.*

FDA Label Image

Aimovig 53

Illustration showing a hand removing the cap from a syringe, holding it vertically as part of the preparation for injection. This instructional image is related to the use of AIMOVIG (erenumab-aooe) injection for subcutaneous administration.*

FDA Label Image

Aimovig 54

An instructional illustration showing the fingers pinching the skin on the abdomen, indicating a subcutaneous injection technique. The arrows point downward, emphasizing the skin pinch method for administering a subcutaneous injection.*

FDA Label Image

Aimovig 55

An instructional diagram illustrating the administration of a subcutaneous injection. It shows a hand holding a syringe at a 90-degree angle to the skin and includes a diagram highlighting the recommended injection angle of 45 degrees. The image is relevant to the subcutaneous injection route of the drug AIMOVIG (erenumab-aooe).*

FDA Label Image

Aimovig 56

Illustration showing a hand administering a subcutaneous injection using a syringe into the skin of another person's abdomen. The image focuses on the injection technique, with an arrow indicating downward pressure on the syringe plunger.*

FDA Label Image

Aimovig 57

An instructional illustration showing a hand holding a syringe and injecting a subcutaneous injection into the skin of an arm. A second hand is stabilizing the injection site. This depicts the subcutaneous administration method for the injection dosage form.*

FDA Label Image

Aimovig 58

An instructional illustration showing a hand inserting a syringe into a red sharps disposal container, indicating proper disposal of the used injection device for AIMOVIG (erenumab-aooe) subcutaneous injection.*

FDA Label Image

Aimovig 59

FDA Label Image

Aimovig 60

FDA Label Image

Aimovig 61

FDA Label Image

Aimovig 62

FDA Label Image

Aimovig 63

Packaging label for AIMOVIG (erenumab-aooe) injection, 70 mg/mL single-dose prefilled syringe by Amgen, Inc. The label includes storage instructions, usage caution, and manufacturer information. The blue and white design features the brand and generic names prominently, along with a syringe illustration marked 70 mg/mL. The product is indicated for subcutaneous use only and includes instructions to store refrigerated at 2°C to 8°C.*

FDA Label Image

Aimovig 64

AIMOVIG 70 mg/mL Prefilled Autoinjector injection label by Amgen, Inc. The label shows the proprietary name AIMOVIG with the generic name erenumab-aooe. It specifies the product is for subcutaneous use only, stored refrigerated at 2°C to 8°C (36°F to 46°F), and includes handling instructions such as do not freeze, do not shake, and discard unused portions. Safety warnings and manufacturer contact information are also present.*

FDA Label Image

Aimovig 65

AIMOVIG 140 mg/mL Injection prefilled autoinjector label. The label includes the proprietary name AIMOVIG with the generic name erenumab-aooe, dosage form as injection, and strength as 140 mg/mL. It indicates the product is for subcutaneous use only and provides storage instructions to keep refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton, avoiding freezing and shaking. The label also features usage and safety warnings and is labeled by Amgen, Inc.*

FDA Label Image

Aimovig 66

AIMOVIG (erenumab-aooe) Injection 140 mg/mL single-dose prefilled syringe packaging label. The label shows product name, strength, dosage form, subcutaneous route, and storage instructions from Amgen, Inc. It includes dosing information indicating 1 dose per syringe and cautions about reading instructions before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.